#BDSX hashtag - Bluesky

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights Biodesix (NASDAQ: BDSX) reported strong Q4 2025 results with $28.8M revenue, 83% Q4 gross margin, and the company’s first-ever positive Adjusted EBITDA of $0.5M. Fiscal 2025 revenue was $88.5M (+24% YoY) and net loss improved to $35.3M.The company finished with pro forma cash of $33.7M (including ATM), amended its term loan to November 2028, and guided FY2026 revenue to $106–112M (midpoint +23%).

1 month ago

#BDSX Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights

www.stocktitan.net/news/BDSX/biodesix-annou...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

2 months ago

Most Searched, Monday January 12, 2026 – Crystal Equity Research

Most searched small-cap stocks, Mon Jan 12th - #SATL #LVLU #RXRX #DNN #CLSK #LAC #NVTX #RZLV #RDW #BTBT #BITF #BDSX #PLUG #UAMY #RR #OCUL #HYMC #EVRV #IBRX #ABAT - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) Biodesix, Inc. (Nasdaq: BDSX) (the company), a

2 months ago

#BDSX Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

www.stocktitan.net/news/BDSX/biodesix-annou...

0 0 0 0

Biodesix Announces Third Quarter 2025 Results and Highlights Biodesix (NASDAQ: BDSX) reported Q3 2025 revenue of $21.8M, up 20% year‑over‑year, and a gross margin of 81%, a 400‑basis‑point improvement versus Q3 2024. Development Services revenue grew 97% YoY and dollars under contract reached $12.9M. The company raised full‑year 2025 revenue guidance to $84–86M and expects to reach Adjusted EBITDA positivity in Q4 2025. Q3 net loss narrowed to $8.7M; cash and equivalents were $16.6M at quarter end, impacted by a $5.2M increase in accounts receivable.Management cited primary care expansion, payer improvements, and a Bio‑Rad partnership as drivers.

5 months ago

#BDSX Biodesix Announces Third Quarter 2025 Results and Highlights

www.stocktitan.net/news/BDSX/biodesix-annou...

0 0 0 0

Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions

5 months ago

#BDSX Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting

www.stocktitan.net/news/BDSX/biodesix-to-sh...

0 0 0 0

Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays Biodesix (NYSE:BDSX) announced on Oct 22, 2025 an expanded partnership with Bio-Rad to develop, clinically validate, and pursue regulatory clearance for Droplet Digital PCR (ddPCR) in vitro diagnostic assays on Bio-Rad's QX600 platform.Key first-step work includes validation of Bio-Rad's ddPLEX ESR1 Mutation Detection Assay for HR+/HER2- advanced breast cancer, manufacturing and distribution of specimen collection kits after clearance, offering the assay as a test at Biodesix's CLIA-CAP laboratory, and seeking CMS reimbursement. Both companies will present further details at AMP, Nov 11-15, 2025 in Boston.

5 months ago

#BDSX Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays

www.stocktitan.net/news/BDSX/biodesix-annou...

0 0 0 0

Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting Biodesix (Nasdaq: BDSX) announced presentations and events at the CHEST 2025 Annual Meeting, October 19–22 in Chicago. Preliminary CLARIFY study data from the first 1,000 enrolled patients will be presented in a sponsored Learning Theater on October 21 at 2:00 PM CDT by Michael Kammer, PhD.The CLARIFY study is a real-world retrospective review designed to assess Nodify CDT and Nodify XL2 performance in up to 4,000 patients with ≥1-year follow-up. Multiple independent clinical presentations and a national analysis of pulmonary nodule healthcare resource utilization will also be presented. Biodesix leadership will staff booth #1012.

5 months ago

#BDSX Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting

www.stocktitan.net/news/BDSX/biodesix-annou...

0 0 0 0

Biodesix Earnings: Revenue Jumps 12%, Development Services Surge 53% as Q4 Profitability Target Nears Diagnostic leader expands PCP network, driving 100%+ test order growth. Development services hit record $12.5M contracts. See Q4 profitability timeline. Get insights.

7 months ago

#BDSX Biodesix Announces Second Quarter 2025 Results and Highlights

www.stocktitan.net/news/BDSX/biodesix-annou...

0 0 0 0

10 months ago

🚨 FeetrAI Alert: #BDSX is in the spotlight! Trading at $0.2906, it's showing bearish vibes with RSI < 40. Despite market bullishness, this penny stock is underperforming. Short at $0.295? Targets: $0.280 & $0.270. Stop loss: $0.305. Risky but rewarding? 📉💡 #Stocks #Trading

0 0 0 0

10 months ago

🚀 Exciting times for #BDSX! Trading at $0.3107, Biodesix shows potential bullish momentum with a positive MACD and consolidation around $0.30. Consider a LONG position targeting $0.33 & $0.35, but stay cautious with a stop loss at $0.29. Speculative play alert! 📈 #FeetrAI

0 0 0 0

10 months ago

🚨 FeetrAI Alert: #BDSX is in the spotlight! Trading at $0.3187, it's showing bearish vibes with RSI < 50 and resistance from 10-day SMA & 20-day EMA. MACD hints at a short-term reversal, but caution is key. Consider shorting with targets at $0.30 & $0.28. Stay sharp! 📉 #Stocks #Trading

0 0 0 0

10 months ago

🚨 FeetrAI Alert: #BDSX is trading at $0.3263 with low volume and a bearish trend below key SMAs. RSI at 42 shows weak momentum, but a slight MACD uptick hints at a possible short-term reversal. Consider a short position with targets at $0.30 & $0.28. Stay sharp! 📉 #Stocks #Trading

0 0 0 0

10 months ago

🚨 FeetrAI Alert: #BDSX is in the spotlight! Trading at $0.321, it's showing oversold conditions with a bearish trend. 📉 Consider a SHORT position with entry at $0.32, targeting $0.30 & $0.28. Stop loss at $0.33. High-risk, high-reward play! Stay tuned for news! 📊 #Stocks #Trading

0 0 0 0

10 months ago

🚨 FeetrAI Alert: #BDSX is in the spotlight! Trading at $0.3102, it's nearing oversold with RSI at 38.6. Volatility is high, but MACD hints at a possible bullish divergence. Consider SHORT at $0.31, targeting $0.28 & $0.26. Stop loss at $0.33. Stay sharp! 📉📈 #Stocks #Trading

0 0 0 0

10 months ago

🚨 FeetrAI Alert: #BDSX is in the spotlight! Trading at $0.3102, it's below key moving averages with RSI under 40. MACD hints at a bounce, but low volume and no news suggest caution. Consider a SHORT at $0.3100, targeting $0.2900 & $0.2700. Stop loss: $0.3200. 📉 #StockWatch

0 0 0 0

10 months ago

🚀 Exciting times for #BDSX! With positive news in cancer diagnostics and a strategic pharma partnership, this stock is poised for a potential bullish reversal. MACD is turning up, RSI shows room to grow. Consider a long position at $0.30, targeting $0.32-$0.34. 📈 #FeetrAI

0 0 0 0

10 months ago

🚨 FeetrAI Alert: #BDSX is in the spotlight! Trading at $0.3206, it's showing bearish vibes with low volume and weak momentum. A SHORT play could be smart—targeting $0.30 & $0.28, stop loss at $0.34. Stay sharp for market shifts! 📉 #StockMarket #FeetrAI

0 0 0 0